Zacks Research Estimates Revvity’s Q2 Earnings (NYSE:RVTY)

Revvity, Inc. (NYSE:RVTY) – Stock analysts at Zacks Research cut their Q2 2025 EPS estimates for Revvity in a report released on Monday, May 19th. Zacks Research analyst R. Department now anticipates that the company will earn $1.15 per share for the quarter, down from their previous estimate of $1.24. The consensus estimate for Revvity’s current full-year earnings is $4.94 per share. Zacks Research also issued estimates for Revvity’s FY2025 earnings at $4.90 EPS, Q2 2026 earnings at $1.31 EPS and FY2026 earnings at $5.44 EPS.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, April 28th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The company had revenue of $664.76 million for the quarter, compared to analyst estimates of $662.30 million. During the same quarter in the prior year, the business posted $0.98 EPS. The firm’s revenue was up 2.3% compared to the same quarter last year.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Company decreased their price target on shares of Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Robert W. Baird decreased their price target on shares of Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, April 29th. KeyCorp raised their price objective on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. UBS Group raised shares of Revvity from a “neutral” rating to a “buy” rating and cut their price target for the company from $145.00 to $115.00 in a report on Thursday, May 1st. Finally, The Goldman Sachs Group cut their price target on shares of Revvity from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Revvity presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.64.

Revvity Stock Down 4.0%

Revvity stock opened at $89.86 on Wednesday. The firm has a 50 day moving average price of $97.62 and a 200-day moving average price of $109.81. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41. Revvity has a twelve month low of $88.53 and a twelve month high of $129.50. The company has a market capitalization of $10.59 billion, a P/E ratio of 40.66, a P/E/G ratio of 3.82 and a beta of 1.02.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 8th. Stockholders of record on Friday, July 18th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.31%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio (DPR) is 11.91%.

Hedge Funds Weigh In On Revvity

Several hedge funds and other institutional investors have recently modified their holdings of the company. Focus Partners Wealth increased its position in shares of Revvity by 13.0% during the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock valued at $744,000 after buying an additional 811 shares during the period. MBB Public Markets I LLC purchased a new position in shares of Revvity during the first quarter valued at about $312,000. United Services Automobile Association purchased a new position in shares of Revvity during the first quarter valued at about $301,000. Goldman Sachs Group Inc. increased its position in shares of Revvity by 45.5% during the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock valued at $64,232,000 after buying an additional 189,871 shares during the period. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of Revvity during the first quarter valued at about $14,765,000. 86.65% of the stock is owned by institutional investors.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.